Expression of two different cholecystokinin receptors in Xenopus oocytes injected with mRNA from rabbit pancreas and rat hippocampus.
Electrophysiological responses to cholecystokinin (CCK) were studied in Xenopus oocytes injected with mRNA from rabbit pancreas or rat hippocampus. CCK-octapeptide(26-33) (sulfated form) (CCK-8) elicited inward currents in both groups. In oocytes injected with pancreatic mRNA, CCK-8-induced currents were composed of two components, fast and slow. However, in oocytes injected with hippocampal mRNA, fast currents disappeared. The potency ranking of the agonists and the antagonist indicated that the receptors expressed by pancreatic and hippocampal mRNA were CCKA- and CCKB-subtypes, respectively. Extracellular application of EGTA had little effect on the CCKB-mediated response, but attenuated the CCKA-mediated one. Intracellular injection of EGTA abolished the CCKB-mediated response, whereas small smooth currents remained in oocytes expressing the CCKA-receptor. The reversal potentials of the CCKA- and CCKB-receptor-mediated responses were consistent with that for CI- currents. However, the reversal potential of the small smooth currents in EGTA-loaded oocytes expressing the CCKA-receptors was close to that for a non-selective cation channel. These results suggest that CCK-8 activates at least two different channels, a Ca(2+)-dependent Cl- channel and a non-selective cation channel in oocytes expressing the CCKA-receptor, while the CCKB-receptor elicits only a Ca(2+)-dependent Cl- channel.
Shionogi Research Laboratories, Shionogi and Co., Ltd, Osaka, Japan.
Y
Y
Shigeri
S
S
Shinohara
S
S
Murata
M
M
Fujimoto
K
K
Kawasaki
D000818:Animals; D002118:Calcium / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004533:Egtazic Acid / Q000494:pharmacology; D015870:Gene Expression; D006727:Hormone Antagonists / Q000494:pharmacology; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D011804:Quinolines / Q000494:pharmacology; D012333:RNA, Messenger / Q000008:administration & dosage / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000187:drug effects* / Q000378:metabolism; D012844:Sincalide / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D014981:Xenopus
D002614:Chelating Agents; D006727:Hormone Antagonists; D011804:Quinolines; D012333:RNA, Messenger; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C063047:A 65186; D004533:Egtazic Acid; D012844:Sincalide; D002118:Calcium